This session took place on Thursday, Dec. 12, 2024.
YOUTUBE CHAPTERS
0:00 Introduction by moderator Carlos Arteaga, SABCS Co-director from UT Southwestern, Dallas, Texas
1:08 Judy Boughey, Mayo Clinic, Rochester, Minnesota, “Factors Influencing Additional Nodal Disease and Pathologic Nodal Upstaging with Axillary Dissection in Patients with Residual Node-Positive Breast Cancer After Neoadjuvant Chemotherapy Enrolled on Alliance A011202 Clinical Trial.”
9:51 Johannes Holtschmidt, VP Medicine & Research GBG Forschungs GmbH, Neu-Isenberg, Germany. “Axillary surgery after neoadjuvant systemic therapy (NST) for early-stage breast cancer – Treatment algorithms and prognostic impact of residual micrometastases in five neoadjuvant studies.”
17:28 Steffi Hartmann, University of Rostock, Rostock, Germany. “Diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients – results from the prospective AXSANA registry trial (NCT04373655).”
23:57 Melanie Machiels, Universiteit Antwerpen, Antwerp, Belgium. “Ultrahypofractionated versus conventional fractionated sequential boost after whole-breast radiation therapy in breast cancer patients. One-year cosmetic outcomes of a randomized, controlled, phase 3 trial (ULTIMO).”
30:18 Demet Özcan, Aarhus University Hospital, Aarhus, Denmark. “Validation of the association between TILs, ER status and benefit of radiotherapy in node positive, breast cancer patients: a DBCG study.”
38:34 Luke Peppone, University of Rochester Medical Center, Rochester, New York. ” A Nationwide Double-Blind Phase III RCT Comparing Olanzapine and Prochlorperazine for Refractory Chemotherapy-Induced Nausea in NCORP Community Practices.”